SALVINA
Florian Muellershausen - Director
Immunology,
Basel, Switzerland
Salvina Therapeutics is developing antibodies with a novel approach for targeting TNF and TNF superfamily members with the aim of improving their safety and efficacy and facilitating the generation of novel bispecific therapies.